Skip to main content
. 2022 Jul 15;29(7):4970–4980. doi: 10.3390/curroncol29070395

Figure 1.

Figure 1

Participant responses: (a) Among your myelofibrosis patients who started ruxolitinib treatment, how many presented primary and secondary resistance? (b) Among patients who have experienced secondary resistance to ruxolitinib, after how long on average has there been a loss of response to the drug?